Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.

Author: AkhtarShahzad, DesaiAmit, GoldwaterRonald, HanDavid, HowiesonCorrie, KowalskiDonna, LademacherChristopher, PearlmanHelene, RammelsbergDiane, TownsendRobert, YamazakiTakao

Paper Details 
Original Abstract of the Article :
This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CY...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297975/

データ提供:米国国立医学図書館(NLM)

Isavuconazole: A Promising Antifungal Agent With Potential Drug Interactions

My dear researchers, the human body is a complex and intricate system, a desert landscape with many interconnected pathways. This study examines the pharmacokinetic interactions of isavuconazole, a new antifungal agent, with various cytochrome P450 (CYP) substrates, a group of enzymes that play a critical role in drug metabolism. It's like studying how a desert plant interacts with the surrounding soil and nutrients, understanding the complex relationships that exist within an ecosystem.

Navigating the Desert of Drug Metabolism

The study found that isavuconazole can induce CYP2B6, an enzyme that metabolizes certain drugs, leading to potential drug interactions. This is like a desert oasis that can alter the growth patterns of nearby plants. The researchers also found that isavuconazole did not significantly affect other CYP enzymes, highlighting the importance of understanding the specific drug interactions that can occur with this new antifungal agent.

A Journey of Drug Development

This research provides valuable insights into the pharmacokinetic properties of isavuconazole, a promising new antifungal agent. It underscores the importance of careful consideration of potential drug interactions when prescribing this drug and the need for ongoing research to fully understand its effects on drug metabolism. Just as a wise traveler in the desert learns to anticipate and navigate the changing terrain, we must approach drug development and prescribing with a cautious and informed perspective.

Dr. Camel's Conclusion

This study offers a valuable contribution to our understanding of the pharmacokinetic interactions of isavuconazole, a new antifungal agent with potential for treating serious fungal infections. It highlights the importance of considering potential drug interactions and the need for ongoing research to optimize its use in clinical practice. Just as a desert can be a harsh and unforgiving landscape, the human body is a complex and intricate system that requires careful navigation and understanding.

Date :
  1. Date Completed 2018-05-25
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

27273149

DOI: Digital Object Identifier

PMC5297975

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.